Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Imatinib> ?p ?o. }
- Imatinib abstract "Imatinib (INN), marketed by Novartis as Gleevec (Canada, South Africa and the USA) or Glivec (Australia, Europe and Latin America), and sometimes referred to by its investigational name STI-571, is a tyrosine-kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Like all tyrosine-kinase inhibitors, imatinib works by preventing a tyrosine kinase enzyme, in this case BCR-Abl, from phosphorylating subsequent proteins and initiating the signalling cascade necessary for cancer development, thus preventing the growth of cancer cells and leading to their death by apoptosis. Because the BCR-Abl tyrosine kinase enzyme exists only in cancer cells and not in healthy cells, imatinib works as a form of targeted therapy—only cancer cells are killed through the drug's action. In this regard, imatinib was one of the first cancer therapies to show the potential for such targeted action, and is often cited as a paradigm for research in cancer therapeutics.Imatinib has been cited as the first of the exceptionally expensive cancer drugs, costing $92,000 a year. Doctors and patients complain that this is excessive, given that its development costs have been recovered many times over, and that the costs of synthesizing the drug are orders of magnitude lower. In the USA, the patent protecting the active principle will expire on 4 January 2015 while the patent protecting the beta crystal form of the active principal ingredient will expire on 23 May 2019.The developers of imatinib were awarded the Lasker Award in 2009 and the Japan Prize in 2012.".
- Imatinib atcPrefix "L01".
- Imatinib atcSuffix "XE01".
- Imatinib bioavailability "98.0".
- Imatinib casNumber "152459-95-5".
- Imatinib casSupplemental "(mesilate)".
- Imatinib chEBI "45783".
- Imatinib drugbank "DB00619".
- Imatinib fdaUniiCode "BKJ8M8G5HI".
- Imatinib iupacName "4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide".
- Imatinib pubchem "5291".
- Imatinib thumbnail Imatinib2DACS.svg?width=300.
- Imatinib wikiPageExternalLink imatinibmesylate.
- Imatinib wikiPageExternalLink ?ligand=STI.
- Imatinib wikiPageExternalLink WC500022203.pdf.
- Imatinib wikiPageID "561843".
- Imatinib wikiPageRevisionID "606758191".
- Imatinib align "left".
- Imatinib atcPrefix "L01".
- Imatinib atcSuffix "XE01".
- Imatinib bioavailability "98.0".
- Imatinib biologicalTarget ABL_(gene).
- Imatinib biologicalTarget CD117.
- Imatinib biologicalTarget Platelet-derived_growth_factor_receptor.
- Imatinib c "29".
- Imatinib caption "Crystallographic structure of tyrosine-protein kinase ABL complexed with imatinib .".
- Imatinib casNumber "152459".
- Imatinib chebi "45783".
- Imatinib chembl "941".
- Imatinib chemspiderid "5101".
- Imatinib drugbank "DB00619".
- Imatinib eliminationHalfLife "144000.0".
- Imatinib eliminationHalfLife "64800.0".
- Imatinib excretion "Faecal and renal".
- Imatinib h "31".
- Imatinib hasPhotoCollection Imatinib.
- Imatinib image "Imatinib3Dan.gif".
- Imatinib inchi "1".
- Imatinib inchikey "KTUFNOKKBVMGRW-UHFFFAOYAJ".
- Imatinib iupacName "4".
- Imatinib kegg "D08066".
- Imatinib legalAu "S4".
- Imatinib legalCa "Rx-only".
- Imatinib legalUk "POM".
- Imatinib legalUs "Rx-only".
- Imatinib licenceEu "Glivec".
- Imatinib licenceUs "IMATINIB".
- Imatinib medlineplus "a606018".
- Imatinib metabolism "Hepatic".
- Imatinib moaText Tyrosine-kinase_inhibitor.
- Imatinib molecularWeight "493.603".
- Imatinib molecularWeight "589.7".
- Imatinib n "7".
- Imatinib name "Imatinib".
- Imatinib o "1".
- Imatinib pdbComplex "1".
- Imatinib pdbLigand "STI".
- Imatinib pregnancyAu "D".
- Imatinib pregnancyUs "D".
- Imatinib proteinBound "95.0".
- Imatinib pubchem "5291".
- Imatinib routesOfAdministration "Oral".
- Imatinib smiles "Cc1cccNCc4cccCN5CCNC".
- Imatinib stdinchi "1".
- Imatinib stdinchikey "KTUFNOKKBVMGRW-UHFFFAOYSA-N".
- Imatinib tradename "Gleevec, Glivec".
- Imatinib unii "BKJ8M8G5HI".
- Imatinib use Chronic_myelogenous_leukemia.
- Imatinib verifiedrevid "459451238".
- Imatinib width "250".
- Imatinib width "300".
- Imatinib subject Category:Benzanilides.
- Imatinib subject Category:Non-receptor_tyrosine_kinase_inhibitors.
- Imatinib subject Category:Piperazines.
- Imatinib subject Category:Pyridines.
- Imatinib subject Category:Pyrimidines.
- Imatinib type Abstraction100002137.
- Imatinib type Base114618253.
- Imatinib type Chemical114806838.
- Imatinib type Compound114818238.
- Imatinib type Material114580897.
- Imatinib type Matter100020827.
- Imatinib type Part113809207.
- Imatinib type PhysicalEntity100001930.
- Imatinib type Pyridine114692510.
- Imatinib type Pyridines.
- Imatinib type Pyrimidine114999913.
- Imatinib type Pyrimidines.
- Imatinib type Relation100031921.
- Imatinib type Substance100019613.
- Imatinib type Drug.
- Imatinib type DrugProduct.
- Imatinib type FunctionalSubstance.
- Imatinib comment "Imatinib (INN), marketed by Novartis as Gleevec (Canada, South Africa and the USA) or Glivec (Australia, Europe and Latin America), and sometimes referred to by its investigational name STI-571, is a tyrosine-kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML).".
- Imatinib label "Imatinib".
- Imatinib label "Imatinib".
- Imatinib label "Imatinib".
- Imatinib label "Imatinib".
- Imatinib label "Imatinib".
- Imatinib label "Imatinib".